Resmed, Sonic Healthcare and Cochlear: Buy, sell or hold?

These three big healthcare stocks are a mixed bag.

a woman

Healthcare sector stocks have received plenty of publicity in the past 12 months, but which have the best outlook? The following are three healthcare stocks that I rate as buy, hold and sell.

Buy: Resmed
Dividend yield: 1.5%

Resmed (ASX: RMD) shares have strongly outperformed rivals Cochlear (ASX: COH) and Sonic Healthcare (ASX: SHL) over the past 12 months, as it has successfully continued its relentless pursuit of revenue growth. The company, which manufactures sleep apnea devices, in August recorded its 74th consecutive quarter of revenue growth — an 11% rise despite challenging market conditions.

Margins expanded nicely and with around 95% of revenue coming from outside Australia, it stands to be a major beneficiary of a weaker Australian dollar. Particularly pleasing was the growth in Europe, which had been struggling. There’s no reason to think that Resmed will stop delivering record revenue and long term investors should consider buying at any dip in the share price.

Hold: Sonic Healthcare
Dividend yield: 4.0%

Pathology and medical diagnostics market leader Sonic Healthcare has performed admirably in the past 12 months, rising over 18% as profit grew moderately in difficult conditions. Sonic has invested heavily in the US and Europe in recent years to grow volume and is now starting to reap the benefits, as margins are improving with scale. This is expected to continue in the coming years with far less investment required by the company, although revenue growth will probably be more organic than acquisition based.

There don’t appear to be many unknown catalysts to push the share price rapidly higher in the short term so investors may be best waiting until the first half earnings are released in December before deciding to buy or sell.

Sell: Cochlear
Dividend yield: 4.1%

Hearing aid manufacturer Cochlear has had a tough 12 months following a poor full year result and greater competition in its key markets. Cochlear’s share price dropped around 20% over two weeks in May and June when it announced weakness in its key US market and slowing sales pending the release of the company’s newest hearing aid product, the Nucleus 6.

Cochlear has struggled since the recall of its Nucleus 5 in September 2011, and recently lost a lucrative Chinese contract to competitor Sonova. The 1,500-unit contract means that the company can only sell a maximum of 1,200 units to China this financial year, compared to 2,800 last year. Based on a sale price of $30,000 this may amount to over $40 million, or 5% of revenue.

I recently sold my COH shares as I no longer believe the company holds a sustainable competitive advantage in the industry, as cheaper alternatives have become available and competitor offerings have become more appealing.

Healthcare companies don’t pay huge dividends so if you are looking for a stock with a heart-stopping yield, discover The Motley Fool’s favourite income idea for 2013-2014 in our brand-new, FREE research report, including a full investment analysis! Simply click here for your FREE copy of “The Motley Fool’s Top Dividend Stock for 2013-2014.”

More reading


Motley Fool contributor Andrew Mudie does not own shares in any of the companies mentioned.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of January 12th 2022

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

asx share price competitions represented by businessmen arm wrestling
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

person reading news on mobile phone
⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »